We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.75 | 1.60 | 1.80 | 0.00 | 07:36:51 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.34 | 13.57M |
TIDMSTX
RNS Number : 1728U
Shield Therapeutics PLC
31 March 2021
Shield Therapeutics plc
("Shield" or the "Group")
Block Listing 6 Monthly Return
Date: 31 March 2021
Name of applicant: SHIELD THERAPEUTICS PLC Name of scheme: S hield Therapeutics Retention Share Plan ---------------------------------------------- Period of return: From: 01 October 2020 To: 31 March 2021 ------------------------ -------------------- ----- ----------------- Balance of unallotted securities under scheme(s) from previous return: 54,219 ---------------------------------------------- Plus: The amount by which the block scheme(s) has been increased NIL since the date of the last return (if any increase has been applied for): ---------------------------------------------- Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): -14,425 ---------------------------------------------- Equals: Balance under scheme(s) not yet issued/allotted at end of period: 39,794 ---------------------------------------------- Name of applicant: SHIELD THERAPEUTICS PLC Name of scheme: Shield Therapeutics plc 2016 Company Share Option Plan ----------------------------------------------------------- Period of return: From: 01 October 2020 To: 31 March 2021 ------------------------ -------------------------- ------- ---------------------- Balance of unallotted securities under scheme(s) from previous return: 388,079 ----------------------------------------------------------- Plus: The amount by which the block scheme(s) has been NIL increased since the date of the last return (if any increase has been applied for): ----------------------------------------------------------- Less: Number of securities issued/allotted under NIL scheme(s) during period (see LR3.5.7G): ----------------------------------------------------------- Equals: Balance under scheme(s) not yet issued/allotted at end of period: 388,079 ----------------------------------------------------------- Name of applicant: SHIELD THERAPEUTICS PLC Name of scheme: The Shield Therapeutics plc 2016 Long Term Incentive Plan -------------------------------------------------------------- Period of return: From: 01 October 2020 To: 31 March 2021 ------------------------ ---------------------------- ------- ----------------------- Balance of unallotted securities under scheme(s) from previous return: 171,883 -------------------------------------------------------------- Plus: The amount by which the block scheme(s) has NIL been increased since the date of the last return (if any increase has been applied for): -------------------------------------------------------------- Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): -147,610 -------------------------------------------------------------- Equals: Balance under scheme(s) not yet issued/allotted at end of period: 24,273 -------------------------------------------------------------- Name of applicant: SHIELD THERAPEUTICS PLC Name of scheme: Shield Therapeutics Retention and Performance Share Plan ------------------------------------------------------------- Period of return: From: 01 October 2020 To: 31 March 2021 ------------------------ --------------------------- ------- ----------------------- Balance of unallotted securities under scheme(s) from previous return: 1,885,819 ------------------------------------------------------------- Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 2,500,000* ------------------------------------------------------------- Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): -1,207,543 ------------------------------------------------------------- Equals: Balance under scheme(s) not yet issued/allotted at end of period: 3,178,276 -------------------------------------------------------------
*Please note this number is further to the block listing applied for on the 24(th) March 2021 and admitted on 30(th) March 2021. This block listing has been allocated to the Shield Therapeutics Retention and Performance Share Plan in entirety.
Name of contact: Lucy Huntington-Bailey Telephone number of contact: +44 (0) 191 511 8500 -----------------------
For further information, please contact:
Shield Therapeutics plc +44 (0) 191 511 8500 Tim Watts (CEO) Lucy Huntington-Bailey, (Company Secretary and General Counsel) Peel Hunt LLP - Nominated Adviser & Joint Broker +44 (0) 20 7148 8900 James Steel / Christopher Golden finnCap Ltd - Joint Broker +44 (0) 20 7220 0500 Geoff Nash / Alice Lane / Matthew Radley Walbrook PR - Financial PR & IR Adviser +44 (0) 20 7933 8780 Paul McManus / Lianne Cawthorne or shield@walbrookpr.com
About Shield
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru (R) /Accrufer (R) (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's lead product, Feraccru(R)/Accrufer(R), has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer(R) in the US during 2021 through a highly experienced sales and marketing team. Feraccru(R) is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BLREADDFDSEFEFA
(END) Dow Jones Newswires
March 31, 2021 10:00 ET (14:00 GMT)
1 Year Shield Therapeutics Chart |
1 Month Shield Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions